With its reserves depleted, a debt payment due in four weeks and its cash runway stretching only into next month, the ...

AstraZeneca’s newly approved, first-in-class hypertension drug Baxfendy does not clear the bar for effectiveness relative to its price, according to the Institute for Clinical and Economic Review ...

Abbott will award $1 million to the school with the most donations to support student or community health. The second season of the competition ended in December, when the University of Wisconsin’s ...

Pushing back on the concept that there can only be one victor among branded obesity drugmakers, Novo Nordisk CEO Mike Doustdar thinks that investors aren’t seeing the whole picture. As the massive ...

Roughly a year and a half after the approval of Vykat XR, a group of clinicians with deep ties to the Prader-Willi syndrome (PWS) community is flagging potential safety concerns about the rare disease ...

Dermatology drugmaker Leo Pharma and the scattering of patients across the globe with rare skin disease generalized pustular psoriasis (GPP) are circling Aug. 13 on their calendars as the second ...

More than four years after its CAR-T star Carvykti’s initial FDA approval, Legend Biotech has reached a major milestone, posting its first profitable quarter. | Legend Biotech's interim CEO, Alan Bash ...

Eli Lilly’s experimental weight-loss drug retatrutide has yet to be approved by the FDA. | Eli Lilly has filed lawsuits against six U.S. companies, accusing them of selling illegal versions of its ...

With all the fretting from the pharmaceutical industry about competition from China, patent protection losses, price reduction initiatives and other government measures with the potential to hit pr | ...

In a deal announced this week, Alfasigma spent an undisclosed sum to continue its global expansion in immunology.  | Alfasigma will add key drugs like Nordimet through the deal, as well as Nordic ...

Fresenius Kabi is yanking a batch of another product in the U.S., shortly after initiating a separate recall tied to mislabeled pain medicine. | Shortly after initiating a separate recall tied to ...

As Alnylam’s Amvuttra sales disappointed, revenue from BridgeBio’s rival transthyretin amyloidosis (ATTR) drug Attruby came in above analysts’ expectations. | Despite their divergent second-quarter ...